Form 4: Repligen Director Exercises Stock Options Under 10b5-1 Plan

Repligen Corp. Director Glenn P. Muir exercised 3,366 stock options at $26.12 per share, increasing direct common stock ownership to 36,622 shares.

Summary

• Director Glenn P. Muir exercised 3,366 stock options of Repligen Corp. (RGEN) on December 16, 2025.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, which allows for pre-planned future transactions.
• The exercise price for these options was $26.12 per share.
• As a result of the exercise, Muir acquired 3,366 shares of common stock.
• Following this transaction, Muir directly owns 36,622 shares of Repligen common stock.
• The options exercised were fully vested and exercisable, with an expiration date of May 11, 2026.
• Muir continues to beneficially own 3,366 derivative securities (stock options) after this transaction.

Sentiment

Score: 7

Explanation: The exercise of stock options by a director indicates a positive outlook on the company's future performance and value, as it increases their direct equity stake and aligns their interests with shareholders. The transaction being pre-planned under a 10b5-1 plan makes it a routine, expected event.

Positives

• A director exercised stock options, indicating confidence in the company's future value at the exercise price of $26.12.
• Increased direct ownership of common stock by a director, aligning management interests with shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, as it is a transactional report.

Industry Context

This is an insider transaction, which is a routine event in publicly traded companies. It reflects an individual executive's compensation and ownership strategy rather than broader industry trends or competitive dynamics.

Comparison to Industry Standards

• Insider transactions, such as stock option exercises, are standard practice across all industries as a component of executive and director compensation.
• The exercise price of $26.12 provides a specific cost basis for these shares, which can be evaluated against Repligen's current market price and historical performance, similar to how other insider transactions are assessed across the biotech or life sciences sector.

Related Party Transactions

• The transaction involves a director of Repligen Corp. exercising stock options granted by the company, which is a standard related-party dealing within executive compensation.

Stakeholder Impact

• Shareholders: Increased insider ownership may be viewed positively, as it further aligns the director's financial interests with those of the shareholders.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where a director exercised stock options under a pre-planned 10b5-1 arrangement. While it demonstrates continued confidence from the director by increasing their equity stake, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change from a 'hold' position based solely on this filing. Investors should consider broader company fundamentals and market conditions for investment decisions.

Keywords

Repligen, RGEN, Stock Option Exercise, Insider Transaction, Director Ownership, Form 4, Equity Compensation, 10b5-1 Plan